While children under five, particularly those under two, are the most vulnerable, pneumococcal diseases also affect adults.

Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to ...

Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate ...

The CDC revised its pneumococcal pneumonia shot recommendation, saying there is a substantial increase in the risk for ...

The pneumococcal polysaccharide vaccine (PPV) is currently recommended for older adults and high-risk subjects, including patients with chronic obstructive pulmonary disease (COPD) and asthma.

Advisory Committee on Immunization Practices (ACIP) has lowered the recommended age for pneumococcal vaccination from 65 to ...

Pregnant patients in their third trimester and postpartum women showed higher risk for IPD compared with nonpregnant patients.

Vaxcyte (PCVX) announced that the first study participants have been dosed in the second and final stage of the ongoing Phase 2 study of VAX-31 ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that Capvaxive be used to prevent invasive disease ...

Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the Committee for Medicinal Products ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...